The grant provides external validation and modest non-dilutive funding for an expanded clinical program. The key catalyst remains the Phase 2b SAFEGUARD data readout. Monitor enrollment updates and any future data releases from PRISE-hATG.
Drug in focus
SABS drug pipeline →SAB-142
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2b (registrational)
- Time to market
- Potentially 2028-2029 if Phase 2b succeeds, given the registrational trial topline reads out in 2H 2027 and accelerated approval is possible via the C-peptide surrogate endpoint pathway
- Next catalyst
- None dated
What to watchSAB-142 is early-stage but has strong institutional validation and ample cash runway through 2028. The next major catalyst (Phase 2b topline data) is still over a year away, so near-term moves will be driven by enrollment milestones, conference data presentations, and progress on the PRISE-hATG study. The stock carries elevated short interest (~56-61% short ratio), so positive enrollment updates could trigger short squeezes. For investors, this is a pre-revenue binary bet with no near-term FDA decision, sizing accordingly is key.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 7 $3.90entry
- T+1 · 4mo ago −3.33%α −3.02% · $3.77
- T+5 · 4mo ago −7.69%α −8.24% · $3.60
- T+20 · 4mo ago −2.82%α −4.15% · $3.79
- T+60 · 7w ago −18.72%α −20.71% · $3.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
SAB Biotherapeutics announced that Breakthrough T1D awarded a grant to support the PRISE-hATG study evaluating SAB-142 in Stage 3 type 1 diabetes patients 100 days to 2 years from diagnosis. The investigator-led study extends the clinical program beyond the typical 100-day window and complements the ongoing Phase 2b SAFEGUARD trial. SAB BIO will co-fund the study; the grant amount was not disclosed.
Key Facts
- Breakthrough T1D awarded a grant to Dr. Michael Haller at University of Florida for the PRISE-hATG study of SAB-142.
- PRISE-hATG evaluates SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis, extending beyond the typical 100-day window.
- The study is randomized, double-blind, placebo-controlled and harmonized with the Phase 2b SAFEGUARD trial.
- SAB BIO will co-fund the study; grant amount not disclosed.
Financial Impact
Grant amount undisclosed; SAB BIO co-funds the study. No revenue or earnings impact.
Risk Factors
- Clinical trial risk, SAB-142 may fail to meet endpoints in PRISE-hATG or SAFEGUARD.
- Competition from approved T1D therapies (e.g., teplizumab) and other pipeline candidates.
- Cash burn, co-funding adds to expenses; additional financing may be needed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-296936 |
| Document: sabs-ex99_1.htm | 0001193125-26-296936 |
| Document: 0001193125-26-296936-index-headers.html | 0001193125-26-296936 |
| Document: 0001193125-26-296936-index.html | 0001193125-26-296936 |
| Document: 0001193125-26-296936.txt | 0001193125-26-296936 |
Track record
15 reports on SABS
3 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +15.67% at T+20 after the Oct 13, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $2.96 Now $3.00 +1.35% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.00 Now $3.00 0.00% settles Dec 15
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $2.94 Now $3.00 +2.04% settles Dec 4
- Oct 22, 202625d ago 25-NSE Neutral 2/10 Entry $2.84 Now $3.00 +5.63% settles Nov 20
- Oct 13, 20264w ago 8-K Bullish 6/10 Entry $2.68 to $3.07 Now $3.00 +11.94% ▲ +14.55% +18.16% vs SPY
- Oct 13, 20264w ago Press Release Bullish 5/10 Entry $2.68 to $3.10 Now $3.00 +11.94% ▲ +15.67% +19.34% vs SPY
- Jul 7, 202618w ago 8-K Bullish 4/10 Viewing Entry $3.90 to $3.79 Now $3.00 −23.08% ▼ −2.82% −4.15% vs SPY
- May 29, 202624w ago Press Release Neutral 3/10 Entry $3.60 to $3.90 Now $3.00 −16.67% ▲ +8.33% +10.13% vs SPY
- May 12, 202626w ago Press Release Bearish 7/10 Entry $3.62 to $3.31 Now $3.00 +17.13% ▲ +8.56% +6.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers